Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 18 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Bosentan tablets for oral suspension, which are indicated for treating Pulmonary Arterial Hypertension in children. The approval allows Zydus to manufacture the tablets at its facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases